immunoglobulin superfamily member 3Genealiases: EWI-3 · LCDD · V8
Q-omics provides the consensus-scored IGSF3 profile across patient tissues and cancer cell-line models. IGSF3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, IGSF3 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, IGSF3 RNA expression shows 19,454 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UCEC, HNSC, and KIRP as cancer lineages where IGSF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGSF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGSF3 survival associations across molecular data types. IGSF3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGSF3 RNA expression–survival associations across cancer types. High IGSF3 expression shows unfavorable associations in UCEC, LIHC, LGG and BLCA, but favorable associations in KIRC and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for IGSF3 RNA expression.
This table summarizes IGSF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IGSF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGSF3 shows lower tumor expression in KIRC and COAD and higher tumor expression in HNSC, BLCA, LIHC and THCA. The HNSC box plot shows higher IGSF3 RNA expression in tumor versus normal tissue (log2 FC = +1.624, t-test p < 0.001).
This table shows molecular features associated with IGSF3 in patient tissues and cancer cell lines. In patient samples, IGSF3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, IGSF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
